CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 160 filers reported holding CRISPR THERAPEUTICS AG in Q4 2018. The put-call ratio across all filers is 1.91 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $269,000 | -26.3% | 3,558 | +9.2% | 0.02% | -35.7% |
| Q3 2021 | $365,000 | -29.8% | 3,259 | +1.3% | 0.03% | -33.3% |
| Q2 2021 | $520,000 | +25.9% | 3,216 | -5.1% | 0.04% | +13.5% |
| Q1 2021 | $413,000 | +18.3% | 3,390 | +49.1% | 0.04% | +12.1% |
| Q4 2020 | $349,000 | +144.1% | 2,274 | +33.5% | 0.03% | +120.0% |
| Q3 2020 | $143,000 | +286.5% | 1,703 | +92.9% | 0.02% | +200.0% |
| Q1 2020 | $37,000 | +362.5% | 883 | +606.4% | 0.01% | +400.0% |
| Q4 2019 | $8,000 | -68.0% | 125 | -79.5% | 0.00% | -66.7% |
| Q3 2019 | $25,000 | +733.3% | 609 | +915.0% | 0.00% | – |
| Q2 2019 | $3,000 | -25.0% | 60 | -53.8% | 0.00% | -100.0% |
| Q4 2018 | $4,000 | – | 130 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |